Your browser is no longer supported. Please, upgrade your browser.
Settings
CATB Catabasis Pharmaceuticals, Inc. daily Stock Chart
CATB [NASD]
Catabasis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.51 Insider Own8.02% Shs Outstand22.56M Perf Week20.50%
Market Cap37.79M Forward P/E- EPS next Y-1.06 Insider Trans0.00% Shs Float21.23M Perf Month8.06%
Income-30.60M PEG- EPS next Q-0.31 Inst Own40.20% Short Float0.25% Perf Quarter-2.05%
Sales0.30M P/S125.98 EPS this Y-4.40% Inst Trans8.01% Short Ratio0.06 Perf Half Y38.43%
Book/sh0.69 P/B2.43 EPS next Y22.60% ROA-95.90% Target Price4.50 Perf Year38.43%
Cash/sh0.96 P/C1.74 EPS next 5Y- ROE-135.80% 52W Range1.09 - 3.78 Perf YTD12.42%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.69% Beta-
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low53.67% ATR0.16
Employees38 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)61.20 Volatility12.57% 9.68%
OptionableNo Debt/Eq0.21 EPS Q/Q42.70% Profit Margin- Rel Volume1.64 Prev Close1.54
ShortableYes LT Debt/Eq0.00 EarningsMar 15 AMC Payout- Avg Volume846.62K Price1.67
Recom1.00 SMA2017.01% SMA509.49% SMA2006.13% Volume1,356,860 Change8.77%
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
Feb-14-18 08:30AM  Todays Research Reports on Trending Tickers: Catabasis Pharmaceuticals and ImmunoCellular Therapeutics ACCESSWIRE -10.90%
Feb-13-18 08:00AM  Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment Business Wire +24.80%
Jan-09-18 10:42AM  Amgen Announces Acceptance of MAA for Evenity in Europe Zacks
Jan-08-18 05:54PM  Ultragenyx Announces Interim Data from Early Stage Study Zacks
Dec-06-17 02:01AM  Summit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness Day GlobeNewswire
02:00AM  Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day GlobeNewswire
01:01AM  Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day GlobeNewswire
Nov-21-17 08:00AM  Catabasis Pharmaceuticals to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-17 04:32PM  Edited Transcript of CATB earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents -5.88%
Nov-13-17 08:20AM  Analysis: Positioning to Benefit within Catabasis, Flowserve, MGIC Investment, Arrowhead, Silver Spring, and Live Nation Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -6.59%
Nov-09-17 04:17PM  Catabasis Pharmaceuticals posts 3Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress Business Wire
11:55AM  Is Catabasis Pharmaceuticals Inc (CATB) A Financially Sound Company? Simply Wall St.
10:10AM  Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Nov-02-17 08:00AM  Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, November 9 Business Wire -6.12%
Oct-26-17 08:00AM  Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference Business Wire
Oct-06-17 07:30AM  Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy ACCESSWIRE -12.32%
Oct-05-17 11:47AM  Catabasis' DMD Candidate Slows Disease Progression, Stock Up Zacks -6.27%
08:00AM  Today's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals ACCESSWIRE
Oct-04-17 12:38PM  Evidence of Biotech Froth Continues to Mount Bloomberg +7.07%
08:30AM  Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher Zacks
07:44AM  Catabasis's stock rockets after positive trial results of Duchenne muscular dystrophy treatment MarketWatch
04:55AM  Armed with fresh trial data, Catabasis doubles down on Duchenne drug American City Business Journals
04:30AM  Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018 Business Wire
Oct-03-17 08:10AM  Today's Research Reports on Stocks to Watch: Catabasis Pharmaceuticals and Rigel Pharmaceuticals ACCESSWIRE +7.20%
Sep-28-17 08:30AM  Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society Business Wire +21.86%
Sep-27-17 01:47AM  Catella: European Residential Properties Show Large Potential for Appreciation PR Newswire
Sep-14-17 08:00AM  Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD® Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society Business Wire +15.86%
Sep-11-17 10:58AM  Top Ranked Momentum Stocks to Buy for September 11th Zacks
Aug-29-17 07:46AM  Catella AB's Comments on Nasdaq Stockholm's Trading Halt for the Company's Class A-Shares PR Newswire +5.34%
Aug-16-17 03:48AM  Edited Transcript of CATB earnings conference call or presentation 10-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 09:37PM  Catabasis Pharmaceuticals posts 2Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress Business Wire
03:00PM  Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Aug-09-17 08:00AM  Catabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference Business Wire
Jul-27-17 08:00AM  Catabasis Pharmaceuticals to Report Second Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, August 10 Business Wire
Jun-23-17 08:00AM  Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference Business Wire
Jun-08-17 11:00AM  Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference Business Wire
Jun-02-17 08:00AM  Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference Business Wire
May-18-17 10:23AM  J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021 Zacks
May-17-17 03:53PM  Edited Transcript of CATB earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
10:07AM  Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth Zacks
May-12-17 11:34AM  Edited Transcript of CATB earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 04:14PM  Catabasis Pharmaceuticals posts 1Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress Business Wire
03:00PM  Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call Accesswire
Apr-27-17 08:00AM  Catabasis Pharmaceuticals to Report First Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, May 11 Business Wire
Apr-25-17 08:00AM  Catabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD® Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting Business Wire
Apr-18-17 08:00AM  Catabasis Pharmaceuticals to Present at the American Academy of Neurology 69th Annual Meeting Business Wire +10.20%
Mar-23-17 01:04PM  CATABASIS PHARMACEUTICALS INC Financials -6.05%
Mar-17-17 01:48PM  Edited Transcript of CATB earnings conference call or presentation 16-Mar-17 8:30pm GMT Thomson Reuters StreetEvents -8.82%
Mar-16-17 04:30PM  Catabasis Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:11PM  CATABASIS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
04:10PM  Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights Business Wire
07:07AM  Q4 2016 Catabasis Pharmaceuticals Inc Earnings Release - After Market Close
Mar-15-17 08:00AM  Catabasis Pharmaceuticals to Present at Oppenheimers 27th Annual Healthcare Conference Business Wire +8.70%
Mar-13-17 09:32AM  Sarepta's DMD Drug Launch Slow; What's in Store for 2017? Zacks -18.14%
08:00AM  Catabasis Pharmaceuticals to Present at the 2017 Muscular Dystrophy Association Scientific Conference Business Wire
Mar-02-17 08:00AM  Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Developments on Thursday, March 16 Business Wire
Mar-01-17 08:00AM  Catabasis Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference Business Wire
Feb-27-17 07:50AM  How the states newest Duchenne biotechs are getting a boost from patient groups at bizjournals.com
Feb-17-17 02:30PM  Congressman Keating calls pricy Duchenne drug an example of 'gouging' at bizjournals.com
08:00AM  Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer Business Wire
07:05AM  Santhera opens Mass. office as local Duchenne ecosystem grows at bizjournals.com
Feb-02-17 11:08AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catabasis Pharmaceuticals, Inc. Business Wire
07:21AM  Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
07:05AM  Catabasis Pharmaceuticals downgraded by Citigroup
06:27AM  Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
Feb-01-17 03:41PM  Catabasis Drops After Muscular Dystrophy Drug Fails at Investopedia -70.79%
10:45AM  Catabasis Pharmaceuticals Inc (CATB): Whats Next? at Insider Monkey
07:47AM  Catabasis Pharma stock sinks 69% after negative mid-stage clinical trial results for DMD drug at MarketWatch
Jan-31-17 07:55PM  Catabasis shares plummet on Duchenne trial failure at bizjournals.com
04:30PM  Catabasis MoveDMD Part B Results Call scheduled for 4:30 pm ET today
04:11PM  CATABASIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
04:01PM  Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy Business Wire
Jan-23-17 12:32PM  Catabasis Muscular Dystrophy Drug Posts Early Win at Investopedia -7.56%
Jan-19-17 12:20PM  Thursdays Top Biopharma Movers +19.76%
09:08AM  Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug at MarketWatch
08:00AM  Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology Business Wire
Jan-18-17 07:40AM  Will Thermo Fisher (TMO) Beat Earnings Estimates in Q4?
Jan-16-17 07:15AM  Mead Johnson (MJN) Q4 Earnings: Disappointment in Store?
Jan-13-17 06:37AM  ResMed (RMD) Q2 Earnings: Disappointment in the Cards?
Jan-06-17 09:17AM  Will Catabasis Pharmaceuticals (CATB) Continue to Surge Higher?
Jan-05-17 08:00AM  Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry Business Wire +9.07%
Jan-04-17 08:00AM  Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight Business Wire +10.27%
Dec-30-16 08:57AM  New Strong Buy Stocks for December 30th +9.06%
Dec-14-16 06:21PM  How Five Star Quality Care, Inc. (FVE) Stacks Up Against Its Peers at Insider Monkey
Dec-06-16 10:07AM  Catabasis Pharmaceuticals, Inc. :CATB-US: Earnings Analysis: Q3, 2016 By the Numbers : December 6, 2016 +8.80%
Nov-17-16 08:30AM  Catabasis Pharmaceuticals Provides Edasalonexent and Rare Disease Pipeline Updates at Investor Day Business Wire
Nov-16-16 01:00PM  Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Nov-11-16 09:49PM  Edited Transcript of CATB earnings conference call or presentation 10-Nov-16 9:30pm GMT +5.45%
Nov-10-16 05:58PM  Catabasis Pharmaceuticals posts 3Q loss +8.46%
04:30PM  Catabasis Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:10PM  Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights Business Wire
04:08PM  CATABASIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
07:07AM  Q3 2016 Catabasis Pharmaceuticals Inc Earnings Release - After Market Close
Nov-07-16 04:07PM  CATABASIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an +5.41%
Nov-03-16 08:00AM  Catabasis Pharmaceuticals to Host Investor Day in New York City on November 17 Business Wire
Oct-27-16 11:15AM  Catabasis Pharmaceuticals Presents Positive Data for CAT-5571, a Novel Activator of Autophagy, as a Potential Oral Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference Business Wire -13.32%
Oct-26-16 08:00AM  Catabasis Pharmaceuticals to Report Third Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, November 10 Business Wire -5.06%
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has preclinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.